| Literature DB >> 32161110 |
Tian Tian1, Serena Lofftus2, Youdong Pan1, Claire A Stingley1, Sandra L King1, Jingxia Zhao1, Timothy Y Pan1, Rebecca Lock3, Jacob W Marglous4, Kevin Liu5, Hans R Widlund1, Robert C Fuhlbrigge6, Karen Cichowski3, Thomas S Kupper7.
Abstract
We assessed the contribution of IL1 signaling molecules to malignant tumor growth using IL1β-/-, IL1α-/-, and IL1R1-/- mice. Tumors grew progressively in IL1R-/- and IL1α-/- mice but were often absent in IL1β-/- mice. This was observed whether tumors were implanted intradermally or injected intravenously and was true across multiple distinct tumor lineages. Antibodies to IL1β prevented tumor growth in wild-type (WT) mice but not in IL1R1-/- or IL1α-/- mice. Antibodies to IL1α promoted tumor growth in IL1β-/- mice and reversed the tumor-suppressive effect of anti-IL1β in WT mice. Depletion of CD8+ T cells and blockade of lymphocyte mobilization abrogated the IL1β-/- tumor suppressive effect, as did crossing IL1β-/- mice to SCID or Rag1-/- mice. Finally, blockade of IL1β synergized with blockade of PD-1 to inhibit tumor growth in WT mice. These results suggest that IL1β promotes tumor growth, whereas IL1α inhibits tumor growth by enhancing T-cell-mediated antitumor immunity. ©2020 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32161110 PMCID: PMC7596693 DOI: 10.1158/2326-6066.CIR-19-0552
Source DB: PubMed Journal: Cancer Immunol Res ISSN: 2326-6066 Impact factor: 11.151